Nivolumab plus ipilimumab (Nivo + Ipi) is recommended as the first-line standard treatment for patients with advanced esophageal squamous cell carcinoma (aESCC), taking into consideration the patient’s general condition and Programmed cell death ligand 1 (PD-L1) expression. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.